Press releases and news
2024
Camurus’ Interim Report January-March 2024
Notice of annual general meeting 2024 in Camurus (publ)
Camurus Annual Report for 2023
Camurus announces FDA acceptance of NDA submission for Oclaiz™ for treatment of acromegaly
Camurus’ Full Year Report 2023
Camurus appoints Behshad Sheldon as President of Camurus Inc.
Completed enrollment in the POSITANO study of CAM2029 in patients with polycystic liver disease
Change in number of shares and votes in Camurus
Camurus has carried out a directed share issue of 2,000,000 shares at a subscription price of SEK 545 per share, raising gross proceeds of SEK 1,090 million
Camurus intends to carry out a directed share issue of approximately 2 million shares and provides preliminary financial information for FY 2023
Get the latest news from Camurus
Subscribe to receive latest news from Camurus directly to your email.